Shopping Cart 0
Cart Subtotal
USD 0

Medinol Ltd - Product Pipeline Analysis, 2019 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250

Details

Summary

Medinol Ltd (Medinol) is a medical device company that researches, develops and manufactures cardiovascular intervention solutions. The company's products include coronary stent system, bare metal stents, PTCA dilatation catheter, biliary metallic stent and self expanding peripheral stent. Its services comprise research, development, coating, quality control, regulatory affairs, clinical trials and studies, manufacturing, drug elution, traditional polymer coating services, marketing and sales. Medinol uses Flexx2 catheter technology, WiZeCell, eDES coating, and unique manufacturing technology to develop its products. Its stents are cut by water-jet laser from cobalt-chromium alloy panels. The company has operations in Israel and the US. Medinol is headquartered in Tel Aviv, Israel.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Medinol Ltd

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Medinol Ltd Company Overview

Medinol Ltd Company Snapshot

Medinol Ltd Pipeline Products and Ongoing Clinical Trials Overview

Medinol Ltd-Pipeline Analysis Overview

Medinol Ltd-Key Facts

Medinol Ltd-Major Products and Services

Medinol Ltd Pipeline Products by Development Stage

Medinol Ltd Ongoing Clinical Trials by Trial Status

Medinol Ltd Pipeline Products Overview

Elunir Elastomer Drug Eluting Stent

Elunir Elastomer Drug Eluting Stent Product Overview

Elunir Elastomer Drug Eluting Stent Clinical Trial

Elunir Elastomer Drug Eluting Stent-38mm

Elunir Elastomer Drug Eluting Stent-38mm Product Overview

Elunir Elastomer Drug Eluting Stent-38mm Clinical Trial

Elunir Elastomer Drug Eluting Stent-44mm

Elunir Elastomer Drug Eluting Stent-44mm Product Overview

Medinol Ltd-Key Competitors

Medinol Ltd-Key Employees

Medinol Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Medinol Ltd, Recent Developments

Mar 19, 2018: Detroit Medical Center First to Use New Stent for Blocked Blood Vessels

Feb 06, 2018: DMC Heart Hospital is First in Michigan to Use the Narrowest Stent Width Available in the United States to Treat Coronary Disease

Jan 11, 2018: Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR Drug-Eluting Stent

Nov 30, 2017: Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

Oct 30, 2017: Cordis Showcases EluNIR Drug-Eluting Stent at TCT 2017

Oct 30, 2017: Cordis Showcases Medinol's NIRxcell, a cobalt-chromium Bare Metal Coronary Stent at TCT 2017

Oct 26, 2017: Medinol Receives CE Mark for the EluNIR Ridaforolimus-Eluting Coronary Stent System, and announces first commercial implantations

Feb 16, 2017: Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US

Dec 21, 2016: Medinol announces excellent clinical results for EluNIR, a novel Drug Eluting Stent

Nov 07, 2016: Medinol receives approval from the Japanese PMDA to begin clinical study on novel DES

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Medinol Ltd Pipeline Products by Equipment Type

Medinol Ltd Pipeline Products by Development Stage

Medinol Ltd Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

Medinol Ltd Pipeline Products and Ongoing Clinical Trials Overview

Medinol Ltd Pipeline Products by Equipment Type

Medinol Ltd Pipeline Products by Indication

Medinol Ltd Ongoing Clinical Trials by Trial Status

Medinol Ltd, Key Facts

Medinol Ltd, Major Products and Services

Medinol Ltd Number of Pipeline Products by Development Stage

Medinol Ltd Pipeline Products Summary by Development Stage

Medinol Ltd Ongoing Clinical Trials by Trial Status

Medinol Ltd Ongoing Clinical Trials Summary

Elunir Elastomer Drug Eluting Stent-Product Status

Elunir Elastomer Drug Eluting Stent-Product Description

Elunir Elastomer Drug Eluting Stent-BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) EUropean Angiography Study

Elunir Elastomer Drug Eluting Stent-BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis-PK Study

Elunir Elastomer Drug Eluting Stent-BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) in Coronary Stenosis Trial

Elunir Elastomer Drug Eluting Stent-EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

Elunir Elastomer Drug Eluting Stent-Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial

Elunir Elastomer Drug Eluting Stent-38mm-Product Status

Elunir Elastomer Drug Eluting Stent-38mm-Product Description

Elunir Elastomer Drug Eluting Stent-38mm-Prospective, Multi-center, Single-arm, Open-label Clinical Trial, to Further Assess the Safety and Efficacy of Long (38 mm) Ridaforolimus Eluting Stent-EluNIR

Elunir Elastomer Drug Eluting Stent-44mm-Product Status

Elunir Elastomer Drug Eluting Stent-44mm-Product Description

Medinol Ltd, Key Employees

Medinol Ltd, Other Locations

Glossary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Medinol Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Edwards Lifesciences (Israel) Ltd

EndoCross Ltd.

Nicast Ltd

Company Profile

Company Profile Title

Summary

Medinol Ltd (Medinol) is a medical device company that researches, develops and manufactures cardiovascular intervention solutions. The company's products include coronary stent system, bare metal stents, PTCA dilatation catheter, biliary metallic stent and self expanding peripheral stent. Its services comprise research, development, coating, quality control, regulatory affairs, clinical trials and studies, manufacturing, drug elution, traditional polymer coating services, marketing and sales. Medinol uses Flexx2 catheter technology, WiZeCell, eDES coating, and unique manufacturing technology to develop its products. Its stents are cut by water-jet laser from cobalt-chromium alloy panels. The company has operations in Israel and the US. Medinol is headquartered in Tel Aviv, Israel.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Medinol Ltd

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Medinol Ltd Company Overview

Medinol Ltd Company Snapshot

Medinol Ltd Pipeline Products and Ongoing Clinical Trials Overview

Medinol Ltd-Pipeline Analysis Overview

Medinol Ltd-Key Facts

Medinol Ltd-Major Products and Services

Medinol Ltd Pipeline Products by Development Stage

Medinol Ltd Ongoing Clinical Trials by Trial Status

Medinol Ltd Pipeline Products Overview

Elunir Elastomer Drug Eluting Stent

Elunir Elastomer Drug Eluting Stent Product Overview

Elunir Elastomer Drug Eluting Stent Clinical Trial

Elunir Elastomer Drug Eluting Stent-38mm

Elunir Elastomer Drug Eluting Stent-38mm Product Overview

Elunir Elastomer Drug Eluting Stent-38mm Clinical Trial

Elunir Elastomer Drug Eluting Stent-44mm

Elunir Elastomer Drug Eluting Stent-44mm Product Overview

Medinol Ltd-Key Competitors

Medinol Ltd-Key Employees

Medinol Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Medinol Ltd, Recent Developments

Mar 19, 2018: Detroit Medical Center First to Use New Stent for Blocked Blood Vessels

Feb 06, 2018: DMC Heart Hospital is First in Michigan to Use the Narrowest Stent Width Available in the United States to Treat Coronary Disease

Jan 11, 2018: Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR Drug-Eluting Stent

Nov 30, 2017: Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

Oct 30, 2017: Cordis Showcases EluNIR Drug-Eluting Stent at TCT 2017

Oct 30, 2017: Cordis Showcases Medinol's NIRxcell, a cobalt-chromium Bare Metal Coronary Stent at TCT 2017

Oct 26, 2017: Medinol Receives CE Mark for the EluNIR Ridaforolimus-Eluting Coronary Stent System, and announces first commercial implantations

Feb 16, 2017: Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US

Dec 21, 2016: Medinol announces excellent clinical results for EluNIR, a novel Drug Eluting Stent

Nov 07, 2016: Medinol receives approval from the Japanese PMDA to begin clinical study on novel DES

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Medinol Ltd Pipeline Products by Equipment Type

Medinol Ltd Pipeline Products by Development Stage

Medinol Ltd Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

Medinol Ltd Pipeline Products and Ongoing Clinical Trials Overview

Medinol Ltd Pipeline Products by Equipment Type

Medinol Ltd Pipeline Products by Indication

Medinol Ltd Ongoing Clinical Trials by Trial Status

Medinol Ltd, Key Facts

Medinol Ltd, Major Products and Services

Medinol Ltd Number of Pipeline Products by Development Stage

Medinol Ltd Pipeline Products Summary by Development Stage

Medinol Ltd Ongoing Clinical Trials by Trial Status

Medinol Ltd Ongoing Clinical Trials Summary

Elunir Elastomer Drug Eluting Stent-Product Status

Elunir Elastomer Drug Eluting Stent-Product Description

Elunir Elastomer Drug Eluting Stent-BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) EUropean Angiography Study

Elunir Elastomer Drug Eluting Stent-BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis-PK Study

Elunir Elastomer Drug Eluting Stent-BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) in Coronary Stenosis Trial

Elunir Elastomer Drug Eluting Stent-EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study

Elunir Elastomer Drug Eluting Stent-Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial

Elunir Elastomer Drug Eluting Stent-38mm-Product Status

Elunir Elastomer Drug Eluting Stent-38mm-Product Description

Elunir Elastomer Drug Eluting Stent-38mm-Prospective, Multi-center, Single-arm, Open-label Clinical Trial, to Further Assess the Safety and Efficacy of Long (38 mm) Ridaforolimus Eluting Stent-EluNIR

Elunir Elastomer Drug Eluting Stent-44mm-Product Status

Elunir Elastomer Drug Eluting Stent-44mm-Product Description

Medinol Ltd, Key Employees

Medinol Ltd, Other Locations

Glossary

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Medinol Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Edwards Lifesciences (Israel) Ltd

EndoCross Ltd.

Nicast Ltd